MTD · NYSE · Medical - Diagnostics & Research

Mettler-Toledo (MTD)

Precision instruments, inspection systems, and services for laboratories, factories, logistics, and food retail.

$1,445.36
vs last close+14.92 (+1.04%)
Loading prices…

Mettler-Toledo International Inc.MTD
Health Care

Sells precision laboratory instruments, industrial weighing and automation systems, product-inspection equipment, retail scales, software, and related services. Laboratory products contribute most sales, while a global sales-and-service network supports research, quality-control, and manufacturing workflows in regulated customer industries.

Builds precision instruments and services across four product groups: Laboratory Instruments, Industrial Weighing and Automation, Product Inspection, and Retail Weighing Solutions. Laboratory offerings span balances, pipettes, titrators, analytical systems, process sensors, automation, and LabX software; industrial systems combine scales, terminals, data-capture, and control software; inspection equipment detects contaminants and verifies package weight, labels, and contents.

Sells globally through direct market organizations and distributors, with the Americas contributing the largest regional share and Europe and Asia and other countries each contributing substantial shares. A broad service organization generates revenue from the installed base through calibration, uptime, compliance, training, and replacement parts. Demand is tied to research, quality control, manufacturing, logistics, and food retail, while many products must meet weights-and-measures, electrical-safety, and customer-industry standards.

Company facts

CEOPatrick K. Kaltenbach
ListedNov 14, 1997
ExchangeNYSE
HeadquartersColumbus, OH
CountryUnited States
Employees16,600
CIK0001037646
ISINUS5926881054

Market cap$28.91B
EPS (ttm)$44.43
P/E (ttm)32.20
ROE
P/B2,254.21
P/S6.99
Dividend yieldDiv yield
Beta0.83vs XLV 0.75

Price target$1,515.00+5.9%Average of 19 analysts
ConsensusHold11 of 19 analysts
Ratings

Target rangeAs of Sep 21, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Sep 1, 2026RBC CapitalInitiate
Rating: Target:
Rating: Sector PerformTarget: $1,515
Aug 4, 2026Morgan StanleyReiterate
Rating: Target: $1,475
Rating: Equal WeightTarget: $1,450
Aug 3, 2026BarclaysReiterate
Rating: Target: $1,500
Rating: OverweightTarget: $1,575
Aug 3, 2026Stifel NicolausTarget
Target: $1,400
Target: $1,600
Jul 31, 2026JefferiesReiterate
Rating: Target: $1,100
Rating: BuyTarget: $1,580

Next report
Nov 5, 26
in 44 days
EPS estimate
$12.11
Revenue estimate
$1.07B
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Jul '25Nov '25Feb '26May '26Jul '26Nov '26
Reported$12.41$8.19$10.09$11.15$13.36$8.91$11.46Pending
Estimate$11.72$7.88$9.60$10.66$12.80$8.71$10.85$12.11
Surprise+5.9%+3.9%+5.1%+4.6%+4.4%+2.3%+5.6%

RevenueReportedEstimate

Feb '25May '25Jul '25Nov '25Feb '26May '26Jul '26Nov '26
Reported$1.05B$883.7M$983.2M$1.03B$1.13B$947.1M$1.03BPending
Estimate$1.01B$876.6M$957.6M$997.3M$1.10B$943.1M$1.03B$1.07B
Surprise+3.6%+0.8%+2.7%+3.3%+2.3%+0.4%0.0%
Estimate$12.11
ReportedDue Nov 5, 2026
Estimate$1.07B
ReportedDue Nov 5, 2026
View details

Debt to equity16,470.10%
Current ratio112.20%

ProfitabilityRevenueNet incomeNet margin

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$954.5M$1.05B$883.7M$983.2M$1.03B$1.13B$947.1M$1.03B
Net income$211.5M$252.3M$163.6M$202.3M$217.5M$285.8M$169.5M$232.9M
Net margin22.2%24.1%18.5%20.6%21.1%25.3%17.9%22.7%

GrowthOperating income

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Operating income$278.3M$333.7M$219.5M$265.7M$289.9M$343.3M$226.6M$314.5M
YoY growth+0.2%+26.5%−11.9%−0.1%+4.2%+2.9%+3.2%+18.3%

Balance sheet, Jun 30, 2026Cash & short-term investments $51.4M · Total debt $2.11B · Total assets $3.67B · Shareholders' equity $12.8M

Revenue
$1.03B
Operating income
$314.5M
Net income
$232.9M
View details

No dividends on record.

Institutions≈ 102.07%20.45M shares
829 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail
Insiders0.08%16.1K shares
20 holders · as of Sep 1, 2026
Adds to102.15%

20.04M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.

These groups come from separate filings that can overlap, so they add to 102.15%; nothing is left for Other.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
BlackRock, Inc.Institution
9.39%1.88Mas of Jun 30, 2026
Capital International InvestorsInstitution
7.59%1.52Mas of Jun 30, 2026
WCM Investment Management, LLCInstitution
7.37%1.48Mfiled Feb 10, 2022
Vanguard Capital Management LLCInstitution
6.59%1.32Mas of Jun 30, 2026
Vanguard Portfolio Management LLCInstitution
5.04%1.01Mas of Jun 30, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Aug 27, 2026Patrick Kaltenbachofficer: President and CEO−942$1,425.00
Aug 5, 2026Thomas P. Salicedirector−417$1,440.41
Aug 3, 2026Shawn Vadalaofficer: Chief Financial Officer−2,240$1,432.00
Aug 3, 2026Gerry Kellerofficer: Head of Process Analytics−240$1,427.14
Aug 3, 2026Thomas P. Salicedirector−415$1,444.62
View details

  • Agilent Technologies

    Lab analytical instruments rival in pharma and chemical lab workflows.

  • Waters

    Focused HPLC/UPLC and thermal analysis rival in pharmaceutical lab workflows.

Compare

CompanyPriceChange
Mettler-Toledo$1,445.36+1.04%$28.91B32.229.27.0+4.5%
Agilent Technologies$164.69+1.70%$45.75B31.925.16.2+8.1%
Waters$428.72+1.13%$41.62B105.727.49.0+113.3%
Median68.826.37.6+60.7%